Find any stock by ticker or company name
Barcha huquqlar himoyalangan.
10.35
0.00 (0.00%)
Cipher Pharmaceuticals TSE: CPH reported lower second-quarter revenue and earnings as sales of its U.S. Natroba treatment declined, while its Canadian Epuris product posted growth and market-share gains. Management said the company remains focused on expanding commercial channels for Natroba, widening public reimbursement for Epuris and pursuing business-development opportunities.
Cipher Pharmaceuticals Inc. (CPH:CA) Q2 2026 Earnings Call Transcript
There is no data to display
